Drug intelligence / Profile preview

Ixiaro + MBJEV

Development stage
Phase 3
Lead developer
Valneva
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Subcutaneous
01

Overview

Ixiaro + MBJEV is a combination of two Japanese encephalitis vaccines. - **Ixiaro** is an inactivated, adsorbed vaccine derived from the Japanese encephalitis virus (JEV) strain SA14-14-2, produced in Vero cells and formulated with aluminum hydroxide as an adjuvant. It is indicated for active immunization against Japanese encephalitis in individuals aged 2 months and older. The mechanism of action involves inducing neutralizing antibodies against JEV to provide protection from infection[1][3][4][5]. - **MBJEV** refers to the "Mouse Brain-derived Japanese Encephalitis Vaccine," a traditional vaccine prepared by propagating JEV in mouse brain tissue, then inactivating and purifying it. This type of vaccine has been widely used but is being replaced by cell culture-derived vaccines like Ixiaro due to improved safety profiles. This combination would be used for immunization against Japanese encephalitis virus, likely where both types are available or required due to local guidelines or supply issues.

02

Targets

E (Tick-borne encephalitis virus envelope protein)

Beyond the preview

Go deeper on Ixiaro + MBJEV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ixiaro + MBJEV.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call